| Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma BI Rini, ER Plimack, V Stus, R Gafanov, R Hawkins, D Nosov, F Pouliot, ... New England Journal of Medicine 380 (12), 1116-1127, 2019 | 3086 | 2019 |
| Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma GK Abou-Alfa, G Lau, M Kudo, SL Chan, RK Kelley, J Furuse, ... NEJM evidence 1 (8), EVIDoa2100070, 2022 | 781 | 2022 |
| Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 … SM Swain, D Miles, SB Kim, YH Im, SA Im, V Semiglazov, E Ciruelos, ... The Lancet Oncology 21 (4), 519-530, 2020 | 731 | 2020 |
| Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open … T Powles, ER Plimack, D Soulières, T Waddell, V Stus, R Gafanov, ... The Lancet Oncology 21 (12), 1563-1573, 2020 | 672 | 2020 |
| Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial T Powles, T Csőszi, M Özgüroğlu, N Matsubara, L Géczi, SYS Cheng, ... The Lancet Oncology 22 (7), 931-945, 2021 | 514 | 2021 |
| Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis J Larkin, B Chmielowski, CD Lao, FS Hodi, W Sharfman, J Weber, ... The oncologist 22 (6), 709-718, 2017 | 269 | 2017 |
| Anaplastic large cell lymphoma associated with breast implants: a report of 13 cases TN Aladily, LJ Medeiros, MB Amin, N Haideri, D Ye, SJ Azevedo, ... The American journal of surgical pathology 36 (7), 1000-1008, 2012 | 183 | 2012 |
| A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the … CS Fuchs, S Azevedo, T Okusaka, JL Van Laethem, LR Lipton, H Riess, ... Annals of Oncology 26 (5), 921-927, 2015 | 179 | 2015 |
| Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of … BI Rini, ER Plimack, V Stus, T Waddell, R Gafanov, F Pouliot, D Nosov, ... Journal of Clinical Oncology 39 (15_suppl), 4500-4500, 2021 | 133 | 2021 |
| Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor … BI Rini, ER Plimack, V Stus, R Gafanov, R Hawkins, D Nosov, F Pouliot, ... Journal of Clinical Oncology 37 (15_suppl), 4500-4500, 2019 | 132 | 2019 |
| Survival after first recurrence of breast cancer. The Miami experience CL Vogel, S Azevedo, S Hilsenbeck, DX East, J Ayub Cancer 70 (1), 129-135, 1992 | 108 | 1992 |
| Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426. ER Plimack, BI Rini, V Stus, R Gafanov, T Waddell, D Nosov, F Pouliot, ... Journal of Clinical Oncology 38 (15_suppl), 5001-5001, 2020 | 77 | 2020 |
| Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: A Clinical … M Royce, T Bachelot, C Villanueva, M Özgüroğlu, SJ Azevedo, FM Cruz, ... JAMA oncology 4 (7), 977-984, 2018 | 65 | 2018 |
| Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426. BI Rini, ER Plimack, V Stus, R Gafanov, T Waddell, D Nosov, F Pouliot, ... Journal of Clinical Oncology 41 (17_suppl), LBA4501-LBA4501, 2023 | 60 | 2023 |
| Burnout in medical oncology fellows: a prospective multicenter cohort study in Brazilian institutions DIG Cubero, RRL Fumis, TH de Sá, A Dettino, FO Costa, BMRHA Van Eyll, ... Journal of Cancer Education 31, 582-587, 2016 | 55 | 2016 |
| Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma B Sangro, SL Chan, RK Kelley, G Lau, M Kudo, W Sukeepaisarnjaroen, ... Annals of Oncology 35 (5), 448-457, 2024 | 46 | 2024 |
| Health-related quality of life analysis from KEYNOTE-426: pembrolizumab plus axitinib versus sunitinib for advanced renal cell carcinoma J Bedke, BI Rini, ER Plimack, V Stus, R Gafanov, T Waddell, D Nosov, ... European Urology 82 (4), 427-439, 2022 | 46 | 2022 |
| Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial AO Siefker-Radtke, N Matsubara, SH Park, RA Huddart, EF Burgess, ... Annals of Oncology 35 (1), 107-117, 2024 | 39 | 2024 |
| Erythema nodosum heralding recurrent Hodgkin's disease S Simon, SJ Azevedo, JJ Byrnes Cancer 56 (6), 1470-1472, 1985 | 39 | 1985 |
| Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung … A Ardizzoni, S Azevedo, B Rubio-Viqueira, D Rodríguez-Abreu, ... Journal for Immunotherapy of Cancer 9 (3), 2021 | 38 | 2021 |
